The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027.
The growth of the market is driven by the factors such as, growing cancer prevalence in North American region and new product launches & FDA approvals. However, the market is likely to slower down its growth due to the lack of reimbursement policies for cancer diagnosis in the region.
Frequent FDA approvals and product launches fuel the growth of the market for cancer tissue diagnostics. Most of the major market players are involved in the manufacturing wide range of cancer diagnostics products that offer maximum advantages and early diagnosis. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Furthermore, In March 2018, Agilent Technologies Inc. launched a new color for immunohistochemistry: HRP Magenta for Dako Omnis. The latest staining characteristics of the chromogen will help it for the assessment of skin and lung tissue. Thus, the constant developments in technology in diagnostics along with, FDA approvals accelerate the market growth during the forecast period.
US is expected to lead the market in the North America region owing to increasing prevalence of cancer, improved diagnosis and treatment of the condition along with the advancements made by market players. Moreover, the country has several hospitals, super specialty hospitals which offers diagnostic and treatment services for the cardiovascular diseases. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.
NORTH AMERICA CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION
By Test Type
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 923.79 Million |
| Market Size by 2027 | US$ 1,587.38 Million |
| CAGR (2019 - 2027) | 6.5% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By Test Type
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
The North America Cancer Tissue Diagnostics Market is valued at US$ 923.79 Million in 2018, it is projected to reach US$ 1,587.38 Million by 2027.
As per our report North America Cancer Tissue Diagnostics Market, the market size is valued at US$ 923.79 Million in 2018, projecting it to reach US$ 1,587.38 Million by 2027. This translates to a CAGR of approximately 6.5% during the forecast period.
The North America Cancer Tissue Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Cancer Tissue Diagnostics Market report:
The North America Cancer Tissue Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Cancer Tissue Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Cancer Tissue Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For North America Cancer Tissue Diagnostics Market
